CureVac puts first COVID-19 vaccine program out of its misery
German mRNA specialist CureVac (Nasdaq: CVAC) was once so strongly fancied as a frontrunner in the race to develop a COVID-19 vaccine that the US government was rumored to be interested in acquiring the company.
Trial results that fell short of the level required for statistical success along with CureVac being overtaken by other vaccine developers have knocked two-thirds off the market value of the company in the last 18 months.
"The requirements to effectively address the virus and emerging variants have changed"On Tuesday, CureVac announced that it was withdrawing its first vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA), sending shares around 7% lower in early trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze